Khiron Life Sciences (CVE:KHRN) and 48North Cannabis (CVE:NRTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.
Valuation & Earnings
This table compares Khiron Life Sciences and 48North Cannabis' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Khiron Life Sciences | C$8.01 million | 9.09 | C$-39,493,921.00 | C($0.26) | -1.84 |
48North Cannabis | C$17.36 million | 1.82 | C$-59,218,395.00 | C($0.26) | -0.53 |
Khiron Life Sciences has higher earnings, but lower revenue than 48North Cannabis. Khiron Life Sciences is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations for Khiron Life Sciences and 48North Cannabis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Khiron Life Sciences | 0 | 0 | 0 | 0 | N/A |
48North Cannabis | 0 | 0 | 0 | 0 | N/A |
Khiron Life Sciences currently has a consensus target price of C$1.20, indicating a potential upside of 147.42%. Given Khiron Life Sciences' higher probable upside, analysts clearly believe Khiron Life Sciences is more favorable than 48North Cannabis.
Profitability
This table compares Khiron Life Sciences and 48North Cannabis' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Khiron Life Sciences | N/A | N/A | N/A |
48North Cannabis | N/A | N/A | N/A |
Summary
Khiron Life Sciences beats 48North Cannabis on 3 of the 5 factors compared between the two stocks.